Want to see ZYBT full AI Analyst Report?
Top Page
Zhengye Biotechnology Holding Ltd.
(NASDAQ:ZYBT)
Select Model
Select Model
Rating:45Neutral
Price Target:
$1.00
▼(-11.50% Downside)
Action:Reiterated
Date:09/15/26
The score is primarily weighed down by deteriorating financial performance—sharp revenue decline and a large 2025 loss alongside weaker operating and free cash flow. Technicals add modest pressure with weak momentum and the stock below key short-term averages, while valuation remains unattractive on an earnings basis due to negative P/E and no dividend support.
Positive Factors
Moderate Leverage
Moderate leverage and a sizable equity base provide a financial cushion despite the 2025 loss. This reduces balance-sheet strain relative to a highly indebted structure and preserves some capacity to manage operations or fund recovery if earnings improve.
Negative Factors
Severe Revenue and Profit Decline
The sharp revenue contraction and move from positive profitability to a very large net loss indicate a fundamental deterioration in demand, pricing, or cost control. Unless reversed, this weakens reinvestment capacity, competitive resilience, and the reliability of future earnings.
Read all positive and negative factors
Positive Factors
Negative Factors
Moderate Leverage
Moderate leverage and a sizable equity base provide a financial cushion despite the 2025 loss. This reduces balance-sheet strain relative to a highly indebted structure and preserves some capacity to manage operations or fund recovery if earnings improve.
Read all positive factors
Zhengye Biotechnology Holding Ltd. (ZYBT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$36.86M
Dividend YieldN/A
Average Volume (3M)32.13K
Price to Earnings (P/E)―
Beta (1Y)-0.49
Revenue Growth-37.53%
EPS Growth-717.42%
CountryUS
Employees269
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)N/A
Shares Outstanding10,965,000
10 Day Avg. Volume17,478
30 Day Avg. Volume32,127
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.52
Price to Sales (P/S)3.27
P/FCF Ratio541.63
Enterprise Value/Market Cap7.40M
Enterprise Value/Revenue3.41M
Enterprise Value/Gross Profit41.08M
Enterprise Value/Ebitda-6.59M
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Zhengye Biotechnology Holding Ltd. Business Overview & Revenue Model
Company Description
Zhengye Biotechnology Holding Limited specializes in the creation, manufacturing, and commercialization of animal health immunizations. The company primarily supplies the Chinese agricultural sector with vaccines tailored for a broad spectrum of f...
Zhengye Biotechnology Holding Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
41
Neutral
| Breakdown | Dec 2025 | Jun 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 116.36M | 186.36M | 211.65M | 260.27M | 214.07M |
| Gross Profit | 23.87M | 91.30M | 129.85M | 153.52M | 125.39M |
| EBITDA | -42.52M | 42.60M | 72.10M | 85.55M | 70.12M |
| Net Income | -69.78M | 11.31M | 31.46M | 46.73M | 38.96M |
Balance Sheet | |||||
| Total Assets | 436.47M | 493.25M | 499.89M | 519.67M | 445.28M |
| Cash, Cash Equivalents and Short-Term Investments | 51.89M | 20.04M | 16.30M | 9.75M | 6.28M |
| Total Debt | 75.08M | 86.43M | 89.85M | 64.88M | 30.00M |
| Total Liabilities | 129.76M | 140.71M | 160.62M | 162.81M | 126.44M |
| Stockholders Equity | 249.85M | 283.96M | 272.85M | 296.50M | 267.47M |
Cash Flow | |||||
| Free Cash Flow | 703.00K | 13.27M | 36.58M | -9.99M | 5.41M |
| Operating Cash Flow | 13.33M | 41.05M | 48.18M | 17.34M | 31.81M |
| Investing Cash Flow | -12.63M | -27.66M | -11.77M | -27.33M | -26.27M |
| Financing Cash Flow | 32.31M | -22.13M | -18.98M | 13.46M | -3.05M |
Zhengye Biotechnology Holding Ltd. Technical Analysis
Negative
1.13
Price Trends
1.56
Negative
1.29
Negative
1.15
Positive
Market Momentum
-0.10
Positive
40.22
Neutral
18.52
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZYBT, the sentiment is Negative. The current price of 1.13 is below the 20-day moving average (MA) of 1.38, below the 50-day MA of 1.56, and below the 200-day MA of 1.15, indicating a neutral trend. The MACD of -0.10 indicates Positive momentum. The RSI at 40.22 is Neutral, neither overbought nor oversold. The STOCH value of 18.52 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ZYBT.
Zhengye Biotechnology Holding Ltd. Risk Analysis
Zhengye Biotechnology Holding Ltd. disclosed 71 risk factors in its most recent earnings report. Zhengye Biotechnology Holding Ltd. reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
Our dual class share structure with different voting rights may adversely affect the value and liquidity of the Class A Ordinary Shares. Q4, 2025
2.
Our dual class share structure with different voting rights will limit your ability to influence corporate matters and could discourage others from pursuing any change of control transactions that holders of our Class A Ordinary Shares may view as beneficial. Q4, 2025
3.
Future issuances of Class B Ordinary Shares may be dilutive to holders of Class A Ordinary Shares. Q4, 2025
Zhengye Biotechnology Holding Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $28.27M | -0.65 | -17.14% | ― | -10.97% | 71.83% | |
54 Neutral | $22.49M | -1.78 | -52.89% | ― | -13.27% | 27.11% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $36.86M | -5.57 | -26.78% | ― | -37.53% | -717.42% | |
43 Neutral | $22.61M | -1.30 | -3.48% | ― | -8.04% | -100.01% |
* Healthcare Sector Average
ZYBT
Zhengye Biotechnology Holding Ltd.
1.24
-1.64
-56.94%
CPHI
China Pharma Holdings
0.66
-1.21
-64.87%
AYTU
Aytu BioScience
2.07
-0.12
-5.48%
SXTC
China SXT Pharmaceuticals
2.41
-19,677.59
-99.99%
BGM
Qilian International Holding Group Limited
9.34
-287.81
-96.86%
UPC
Universe Pharmaceuticals
4.50
-0.24
-5.06%
Zhengye Biotechnology Holding Ltd. Corporate Events
Zhengye Biotechnology Regains Nasdaq Minimum Bid Price Compliance
Aug 6, 2026
On August 5, 2026, Zhengye Biotechnology Holding Limited received confirmation from Nasdaq that it had regained compliance with the exchange’s minimum bid price requirement of $1.00 per share. This followed a prior notice on May 29, 2026 tha...
Zhengye Biotechnology Addresses Unusual Nasdaq Trading Activity
Jul 21, 2026
Zhengye Biotechnology Holding Limited, a Jilin-based veterinary vaccine producer with around 50 products for livestock and companion animals, sells across most of China and into markets such as Vietnam, Pakistan and Egypt. Its vertically integrate...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.